Monitor for any competitive shifts in HAE prophylaxis market share based on real-world evidence; navenibart interim results may influence pipeline valuation if positive.
Drugs in focus
BCRX drug pipeline →navenibart
◆ Mixed Named in this press release- Impact
- Phase
- Phase 3
- Time to market
- Assuming positive Phase 3 data (Q3 2027), a US regulatory filing would follow around end-2027, with potential approval in 2028-2029.
- Next catalyst
- None dated
What to watchNavenibart is a promising long-term pipeline story within BioCryst, but there is no imminent binary catalyst for ~12+ months. Investors should watch for interim data updates at medical conferences and the pivotal Phase 3 ALPHA-ORBIT readout in Q3 2027. In the meantime, near-term BCRX value is driven by ORLADEYO commercial execution and the ongoing business restructuring.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $7.61entry
- T+1 · 20h ago −2.10%α −0.19% · $7.45
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BioCryst presented two real-world studies at ACAAI 2026 showing that ORLADEYO (berotralstat) reduces hospitalizations and emergency department visits in HAE patients, both in treatment-naïve initiators and in patients switching from another prophylactic therapy. The data support ORLADEYO's clinical and economic profile but are not a regulatory or commercial catalyst.
Key Facts
- ORLADEYO is the first and only targeted oral prophylactic therapy for HAE in patients aged 2 and older.
- Study 1 (n=78): Patients switching to ORLADEYO from another LTP saw a 30% reduction in overall angioedema-related visits (p=0.039) and a 30% reduction in outpatient/ED visits (p=0.040).
- Study 2 (n=128 ORLADEYO, n=236 lanadelumab, n=95 SC-pdC1-INH): All cohorts had statistically significant reductions in ED visits; ORLADEYO showed a 53% reduction in all-cause hospitalizations and a 61% reduction in angioedema-related ED visits.
- No statistically significant differences in magnitude of reductions were observed between ORLADEYO and lanadelumab or SC-pdC1-INH.
- BioCryst also presented interim data on navenibart (investigational monoclonal antibody) with potential best-in-class dosing every 3 or 6 months.
Financial Impact
No financial figures provided; real-world data may support ORLADEYO's market positioning but no revenue or guidance impact stated.
Risk Factors
- Real-world data are observational and may not reflect controlled trial outcomes.
- No statistically significant differentiation from lanadelumab or SC-pdC1-INH could limit commercial advantage.
- Navenibart is investigational; clinical development risks remain.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3402489 |
Track record
20 reports on BCRX
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +21.01% at T+20 after the Feb 26, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.71 Now $7.45 −3.35% settles Feb 16
- Nov 13, 20263d ago Press Release Neutral 3/10 Viewing Entry $7.61 Now $7.45 −2.10% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $7.53 Now $7.45 −1.06% settles Feb 8
- Nov 4, 202612d ago 8-K Bullish 6/10 No price data
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $8.24 Now $7.45 −9.59% settles Feb 2
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $8.57 Now $7.45 −13.07% settles Feb 1
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $8.37 Now $7.45 −10.99% settles Jan 26
- Oct 21, 202626d ago Press Release Neutral 1/10 Entry $7.78 Now $7.45 −4.24% settles Jan 20
- Aug 5, 202614w ago 8-K Bullish 7/10 Entry $9.07 to $8.46 Now $7.45 −17.86% ▼ −6.73% −6.92% vs SPY
- Jun 29, 202620w ago 8-K Neutral 5/10 Entry $9.55 to $8.78 Now $7.45 −21.99% ▼ −8.06% −12.45% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers